Latest Jazz Pharmaceuticals plc Stories
Expanded U.S. Labeling Offers an Alternative Method to Administer Erwinaze to Patients with ALL DUBLIN, Dec.
Expects to complete submission in the first half of 2015 DUBLIN, Dec.
Trial Initiated in Response to a FDA Pediatric Written Request to Study Xyrem in Children and Adolescents DUBLIN, Dec.
Posters Include an Epidemiological Measure of the Effectiveness Analysis of Defibrotide from a Phase 3 Trial in Severe Hepatic VOD, as well as Updates from an International Compassionate Use Program
Company Reports Third Quarter 2014 Total Revenues of $307 Million, Driven by Strong Sales of Xyrem, Erwinaze and Defitelio DUBLIN, Nov.
Company Reports Second Quarter 2014 Total Revenues of $291 Million, Driven by Strong Sales of Xyrem, Erwinaze and Defitelio DUBLIN, Aug.
- The act of sweetening by admixture of some saccharine substance.